Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting

On April 2, 2026 Palleon Pharmaceuticals, a company developing engineered enzyme therapies that remove excessive sialic acid to treat autoimmune diseases and cancer, reported upcoming presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in San Diego from April 17 – 22. Palleon will make an oral presentation during the "New Drugs on the Horizon" series on Sunday, April 19 and will present a poster on Wednesday, April 22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Palleon’s Presentations:

American Association for Cancer Research Annual Meeting
Title: A First-in-Class Human Sialidase-Armed Anti-B7-H3 Antibody that Enhances Innate and Adaptive Antitumor Immune Responses
Abstract ID: 7158
Oral Presentation Session Date and Time: Sunday, April 19 from 3:00 PM to 4:30 PM PT
Poster Presentation Session Date and Time: Wednesday, April 22 from 9:00 AM to 12:00 PM PT
Session Category: Experimental and Molecular Therapeutics
Session Title: Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy

HLX316/E-688 is a first-in-class investigational treatment developed from Palleon’s EAGLE (Enzyme-Antibody Glycan-Editing) Platform. Palleon’s HLX316/E-688 is being developed in China by Shanghai Henlius Biotech and is designed to address key mechanisms of immune evasion by enhancing the desialylation of tumor cells that express B7-H3 to help restore both innate and adaptive anti-tumor responses in the tumor microenvironment. The China National Medical Products Administration (NMPA) has cleared Henlius’ Investigational New Drug (IND) application for a Phase 1 clinical trial of HLX316/E-688 in China for the treatment of advanced or metastatic solid tumors.

The presentations will be made available on the Glycobiology Education section of Palleon Pharmaceuticals’ website.

(Press release, Palleon Pharmaceuticals, APR 2, 2026, View Source [SID1234664162])